11th Annual Cardiovascular Disease Update

Release Date: November 1, 2017
Expiration Date: October 31, 2020

PROGRAM AGENDA


Track One: Restoring Structural Heart Function

1. Case Presentation; 2. Recent Advances in Percutaneous Mitral Valve Intervention; 3. Left Atrial Appendage Occlusion: Who, When, How and Results; 4. Audience Polling Question and Panel Discussion

More presenters


Track Two: Making a Difference for Patients with PAD

1. Case Presentation; 2. Evolving Challenges in Type 2 DM Management; 3. The ABCs of PAD and CLI in Type 2 DM; 4. High-Risk Patient with Type 2 DM: New Evidence and Goals for Lipid Lowering; 5. Audience Polling Question and Panel Discussion

More presenters


Track Three: Managing Heart Failure and Preventing Sudden Cardiac Death

1. Case Presentation; 2. Advanced Imaging as a Diagnostic and Prognostic Tool in Heart Failure; 3. How to Evaluate Advanced Heart Failure Patients with Continuing Symptoms for Destination Therapies; 4. Mechanical Assist Devices for the ...

More presenters


Plenary Session

Joseph F. Sabik, III, MD discusses the latest in Surgical Coronary Revascularization at University Hospitals Cleveland Medical Center's 11th Annual Cardiovascular Disease Update.

Media

Recorded slides and audio presentation.  Supplementary educational materials may include downloads of videos, print materials, slides or web pages.

Target Audience

This program is intended to update practicing internists, family medicine physicians, primary care physicians, cardiologists, cardiac surgeons, vascular surgeons, physician assistants, nurse practitioners, nurses, residents and fellows on current topics in cardiovascular disease.

Learning Objectives

After participating in this activity, participants will be able to:

  • Review indications for common structural interventions and when to refer patients
  • Define complications with transcatheter aortic valve replacement (TAVR) and follow-up care
  • Review new therapies to lower risk in the diabetic patient with peripheral artery disease (PAD)
  • Explain the impact and longevity of new therapies for critical limb ischemia (CLI)
  • Describe advanced imaging options for evaluation of heart failure patients
  • Discuss indications for mechanical therapies, including durability and efficacy, for heart failure

Accreditation Statement 

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Track One: 0.5 Credits
  • Track Two: 1.0 Credits
  • Track Three: 0.5 Credits
  • Plenary Session: 0.25 Credits

Disclosure Statement

The policy of Case Western Reserve University School of Medicine CME Program (CWRU CME) requires that the Activity Director, planning committee members and all activity faculty (that is, anyone in a position to control the content of the education activity) disclose to the activity participants all relevant financial relationships with commercial interests.  Where disclosures have been made, conflicts of interest, real or apparent, must be resolved.  Disclosure will be made to activity participants prior to the commencement of the activity.  CWRU CME also requires that faculty make clinical recommendations based on the best available scientific evidence and that faculty identify any discussion of "off-label" or investigational use of pharmaceutical products or medical devices.

Instructions

To receive statements of credit for up to 2.25 AMA PRA Category 1 Credits™ you must:

  1. Review the full content of the recorded sessions.
  2. Review any supplementary materials referenced under Resources.
  3. Reflect on the content.
  4. Successfully complete the post-test. A score of 75% is required for passage.
  5. Complete the evaluation.

Your credits will be recorded by the CWRU School of Medicine CME Program and made a part of your cumulative transcript. Credits are awarded on a per-talk basis.

Fee

There is no fee for this program.

To contact the CME Provider: E-mail Case Western Reserve University School of Medicine CME at medcme@case.edu

Medical Disclaimer

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The author has checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.

Although every effort is made to ensure that this material is accurate and up-to-date, it is provided for the convenience of the user and should not be considered definitive.  Neither the author nor the Case School of Medicine nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such information.

Learners are encouraged to confirm the information contained herein with other sources.  This information should not be construed as personal medical advice and is not intended to replace medical advice offered by physicians.  The Case School of Medicine will not be liable for any direct, indirect, consequential, special, exemplary, or other damages arising here from.

Resources

  1. McMurray, John JV, et al. "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012." European journal of heart failure 14.8 (2012): 803-869.https://www.achaheart.org/provider-support/resorces/
  2. Schoen, Frederick J. "Cardiac valves and valvular pathology: update on function, disease, repair, and replacement." Cardiovascular Pathology 14.4 (2005): 189-194.Tsai, TT, et al. “Partial thrombosis of the false lumen in patients with acute type B aortic dissection.” N Engl J Med 2007; 35(4): 349-359.
  3. Gornik, Heather L., and Joshua A. Beckman. "Peripheral arterial disease." Circulation 111.13 (2005): e169-e172.Douglas PS, Hoffmann U, Patel MR et al.  “Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease.”  N Engl J Med  2015;372(14):1291-1300.
  4. Malý, R., and V. Chovanec. "Peripheral arterial disease and diabetes." Vnitrni lekarstvi 56.4 (2010): 341-346.
  5. Kon, Zachary N., et al. "Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass." The Journal of thoracic and cardiovascular surgery 135.2 (2008): 367-375.Hubers SA, Brown NJ.  “Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.”  Circulation.  2016;133:1115-1124.
  6. Raza, Sajjad, et al. "Bilateral versus single internal-thoracic-artery grafts." N Engl J Med 2017 May 4: 376(18):e37.